Lenvatinib plus pembrolizumab in renal cell cancer

Dr. Robert Motzer

The multinational phase 3 CLEAR study compared lenvatinib plus pembrolizumab versus lenvatinib plus everolimus versus sunitinib for advanced renal cell carcinoma. The progression-free survival (primary end point) and overall survival (HR 0.66; p=0.005) were significantly longer with lenvatinib plus pembrolizumab than with sunitinib.